E. Mysler

发表论文 9 篇 · 总被引 9 次 · h-index 2

代表论文

• OP0089 PHASE 2 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED EVERY 4 WEEKS UP TO 48 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (2024 · Scientific Abstracts · 被引 4)
• OP0020 IMMUNOGENICITY OF AN ADJUVANT RECOMBINANT ZOSTER VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB: 60-WEEK RESULTS FROM A RANDOMIZED SUBSTUDY (2024 · Scientific Abstracts · 被引 3)
• POS0407 TYPE I INTERFERON PATHWAY IS UPREGULATED IN GLOMERULAR AND TUBULOINTERSTITIAL KIDNEY COMPARTMENTS OF PATIENTS WITH LUPUS NEPHRITIS AND OTHER RENAL DISEASES (2024 · Scientific Abstracts · 被引 1)
• POS0639 BENEFIT–RISK ANALYSIS OF UPADACITINIB VERSUS ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGHER OR LOWER RISK OF CARDIOVASCULAR DISEASE (2024 · Scientific Abstracts · 被引 1)
• POS0540 Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study (2025 · Annals of the Rheumatic Diseases)
• POS0151 RELATIONSHIP BETWEEN DISEASE ACTIVITY AND ADVERSE EVENTS IN RHEUMATOID ARTHRITIS: AN INTEGRATED POST HOC ANALYSIS OF UPADACITINIB PHASE 3 TRIALS (2025 · Annals of the Rheumatic Diseases)